Academy ’25: New Data Strengthens Evidence for DOT™ Myopia Control Lenses
Monday, October 6 2025 | 16 h 16 min | News
SightGlass Vision presented new data at the American Academy of Optometry 2025 Annual Meeting in Boston showing the continued effectiveness of its DOT™ spectacle lenses for managing childhood myopia.
Stronger 18-Month Outcomes
Interim results from an 18-month study across five hospitals in China found that 57% of children wearing DOT lenses experienced no clinically meaningful myopia progression, nearly four times the rate seen with standard single-vision lenses (15%). DOT wearers also showed significantly less axial length elongation (0.34 mm) and spherical equivalent progression (0.70 D) than the control group.
Canadian Real-World Results
Findings from CU Vision in British Columbia further highlight everyday impact. After two years of DOT lens wear, over half of children had stable refraction (≤0.50 D change), with progression slowed by at least half on average. Outcomes were particularly strong among younger children, who face the highest risk of rapid progression.
Astigmatism and Safety
New analyses presented by Dr. Debbie Laughton indicated that DOT lenses slow myopia progression without increasing astigmatism. Twelve-month results in both North American and Chinese populations showed no difference in astigmatism incidence between DOT wearers and control groups.
Expanding Global Reach
SightGlass Vision, a joint venture of CooperVision and Essilor International, reports that more than one million children worldwide have now worn DOT lenses. Recent market launches include Canada, Spain, the Netherlands, Israel, China, and the U.K.
“Momentum continues to grow, with DOT becoming a globally trusted solution for protecting children’s vision,” said Andrew Sedgwick, CEO of SightGlass Vision.
Click HERE for the full press release.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!
